Skip to main content
Clinical Trials/NL-OMON40728
NL-OMON40728
Completed
Phase 4

ong-term follow-up and cross-over of treatment with high-density micropulse laser and half-dose photodynamic therapy in participants of the PLACE trial for chronic central serous chorioretinopathy. - CROSS-OVER/LONG-TERM FOLLOW-UP STUDY for chronic CSC, following PLACE trial

eids Universitair Medisch Centrum0 sites92 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Chronic central serous chorioretinopathy
Sponsor
eids Universitair Medisch Centrum
Enrollment
92
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
May 30, 2018
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Only participants of the PLACE trial can be enrolled for this study.
  • In the Cross\-over study, the following patients will be included:
  • \- Subjects with persistent SRF on OCT at the final follow\-up visit of the PLACE trial (7\-8 months after Treatment Visit 1 PLACE trial) after either two PDT treatments in or two HSML treatments,
  • \- Subjects with recurrence of SRF on OCT at the final follow\-up visit of the PLACE trial after one PDT or one HSML treatment, will be included in the cross\-over study.
  • Of note, for SRF on OCT does not have to involve the fovea for patients to be included in the cross\-over study.
  • In the Long\-term follow\-up study, the following patients will be included:
  • \- Subjects who do not show any SRF on OCT at final visit of the PLACE trial will be included.
  • Of note, patients who were not initially included in the long\-term follow\-up study, because of persistent SRF on OCT, were automatically included in the cross\-over study.

Exclusion Criteria

  • For this study no exclusion criteria are applicable.

Outcomes

Primary Outcomes

Not specified

Similar Trials